drugset / Trial / NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Timeline
- Start
- 2020-02-19
- Primary completion
- 2024-11-11
- Completion
- 2024-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IOV-2001 | Cell therapy | — | — |
| Subject | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 9e+06 iu | Subcutaneous |